223 related articles for article (PubMed ID: 17918664)
1. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
2. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
[TBL] [Abstract][Full Text] [Related]
4. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
6. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
Zubor P; Kajo K; Stanclova A; Szunyogh N; Galo S; Dussan CA; Minarik G; Visnovsky J; Danko J
Eur J Cancer Prev; 2008 Feb; 17(1):33-8. PubMed ID: 18090908
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
8. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.
Kamali-Sarvestani E; Talei AR; Merat A
Cancer Lett; 2004 Nov; 215(1):83-7. PubMed ID: 15374636
[TBL] [Abstract][Full Text] [Related]
9. Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Puputti M; Sihto H; Isola J; Butzow R; Joensuu H; Nupponen NN
Cancer Genet Cytogenet; 2006 May; 167(1):32-8. PubMed ID: 16682283
[TBL] [Abstract][Full Text] [Related]
10. A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan.
Lee SC; Hou MF; Hsieh PC; Wu SH; Hou LA; Ma H; Tsai SM; Tsai LY
Clin Biochem; 2008 Feb; 41(3):121-5. PubMed ID: 18062925
[TBL] [Abstract][Full Text] [Related]
11. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
12. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer.
Kuraoka K; Matsumura S; Hamai Y; Nakachi K; Imai K; Matsusaki K; Oue N; Ito R; Nakayama H; Yasui W
Int J Cancer; 2003 Nov; 107(4):593-6. PubMed ID: 14520697
[TBL] [Abstract][Full Text] [Related]
13. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
14. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
15. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.
Kalemi TG; Lambropoulos AF; Gueorguiev M; Chrisafi S; Papazisis KT; Kotsis A
Cancer Lett; 2005 May; 222(1):57-65. PubMed ID: 15837541
[TBL] [Abstract][Full Text] [Related]
16. HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis.
Tao W; Wang C; Han R; Jiang H
Breast Cancer Res Treat; 2009 Mar; 114(2):371-6. PubMed ID: 18438707
[TBL] [Abstract][Full Text] [Related]
17. Germ-line HER-2 variant and breast cancer risk by stage of disease.
McKean-Cowdin R; Kolonel LN; Press MF; Pike MC; Henderson BE
Cancer Res; 2001 Dec; 61(23):8393-4. PubMed ID: 11731415
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients.
Sezgin E; Sahin FI; Yagmurdur MC; Demirhan B
Genet Test Mol Biomarkers; 2011 Mar; 15(3):143-6. PubMed ID: 21204706
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
20. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]